6-isopropyl-dihydro-pyrimidine-2,4-dione | 26139-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-isopropyl-dihydro-pyrimidine-2,4-dione
• 英文别名: 6-Isopropyl-dihydro-pyrimidin-2,4-dion；6-Propan-2-yl-1,3-diazinane-2,4-dione
• CAS: 26139-44-6
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.184
• InChiKey: LZSGKTLVUGWOIA-UHFFFAOYSA-N

物化性质

• 熔点：
  192-193 °C(Solv: ethanol (64-17-5); ethanol (64-17-5); benzene (71-43-2)(1:10))
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (2E)-4-methylpent-2-enoic acid 、 尿素 生成 6-isopropyl-dihydro-pyrimidine-2,4-dione
  参考文献：
  名称：

  Birkofer; Storch, Chemische Berichte, 1953, vol. 86, p. 529,532

  摘要：

  DOI：

文献信息

• Thyrotropin-Releasing Hormone Analogs and Method of Use
  申请人：Luo LuGuang

  公开号：US20080249028A1

  公开（公告）日：2008-10-09

  The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented.

  本发明提供了一种使用甲状腺促性腺激素释放激素（TRH）或TRH衍生物治疗或预防胰腺相关疾病来调节血糖水平的方法。首选治疗或预防糖尿病、胰岛破坏、胰岛素β细胞功能障碍和高血糖相关功能障碍。
• Non-beta lactam antibiotics
  申请人：University of Notre Dame du Lac

  公开号：US10662164B2

  公开（公告）日：2020-05-26

  The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.

  本发明提供了一种新发现的噁二唑类抗生素。噁二唑类抗生素会损害细胞壁的生物合成，对革兰氏阳性细菌，如金黄色葡萄球菌，包括耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素金黄色葡萄球菌和耐利奈唑胺金黄色葡萄球菌具有活性。例如，5-(1H-吲哚-5-基)-3-(4-(4-(三氟甲基)苯氧基)苯基)-1,2,4-恶二唑（抗生素 75b）在 MRSA 感染的小鼠模型中疗效显著，半衰期长，分布容积大，清除率低。抗生素 75b 具有杀菌和口服生物利用度高的特点。这一类抗生素可用作治疗革兰氏阳性菌（如 MRSA）感染的药物。
• NON-BETA LACTAM ANTIBIOTICS
  申请人：University Of Notre Dame Du Lac

  公开号：US20190127340A1

  公开（公告）日：2019-05-02

  The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus , including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus . For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.